Vaccine Info

Fluad Quadrivalent Influenza Vaccine

Fluad Quadrivalent Description

Fluad consists of an inactivated, quadrivalent influenza virus antigen produced in eggs and an oil-in-water emulsion adjuvant, MF59C.1.

For 2020-2021, quadrivalent (four-component) egg-based vaccines are recommended to contain:

  • A/Guangdong-Maonan/SWL1536/2019 (H1N1)pdm09-like virus (updated)
  • A/Hong Kong/2671/2019 (H3N2)-like virus (updated)
  • B/Washington/02/2019 (B/Victoria lineage)-like virus (updated)
  • B/Phuket/3073/2013-like (Yamagata lineage) virus.

Fluad Quadrivalent Indication

Fluad is indicated for active immunization against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. 

Fluad Quadrivalent Dosage

Fluad is administered as an intramuscular injection in adults 65 years of age and older.

Fluad helps protect against the same flu strains as other seasonal flu shots, but it has something they don’t have: an immune-enhancing ingredient that can help provide a strong immune response to the flu in adults 65 and older.

Fluad is the first FDA-approved seasonal flu shot that contains an adjuvant, which is an immune-enhancing ingredient.

The immune-enhancing ingredient in Fluad is an oil derived from squalene. Squalene is a naturally occurring substance found in humans, animals, and plants.

Adults aged 65 and older who have an aging immune system might have a lower immune response to traditional flu vaccines compared to younger adults.

Squalene the immune-enhancing ingredient is proven to provide a strong immune response to help the immune systems of adults 65 and older to recognize and respond to the flu virus.

On November 24, 2015, the U.S. Food and Drug Administration sent an approval letter authorizing the introduction or delivery of Fluad into interstate commerce. 

Fluad Quadrivalent Adverse Events

Some adverse events (which are also reported after regular flu vaccines) were reported more frequently after vaccination with FLUAD. The most experienced during clinical studies were mild to moderate and temporary: pain, redness at the injection site, headache, muscle aches, and malaise.

Fluad Quadrivalent News

February 24, 2020 - Seqirus Receives FDA Approval for FLUAD QUADRIVALENT for Adults 65 Years and Older

Updated
07/29/2020 - 10:20